[go: up one dir, main page]

PE20140977A1 - Composicion farmaceutica estabilizada a base de un compuesto no peptidico - Google Patents

Composicion farmaceutica estabilizada a base de un compuesto no peptidico

Info

Publication number
PE20140977A1
PE20140977A1 PE2014000508A PE2014000508A PE20140977A1 PE 20140977 A1 PE20140977 A1 PE 20140977A1 PE 2014000508 A PE2014000508 A PE 2014000508A PE 2014000508 A PE2014000508 A PE 2014000508A PE 20140977 A1 PE20140977 A1 PE 20140977A1
Authority
PE
Peru
Prior art keywords
acid
hydrocarbon group
pharmaceutical composition
dispersed
formula
Prior art date
Application number
PE2014000508A
Other languages
English (en)
Inventor
Yasuhiro Hiraishi
Muneo Nonomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140977(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20140977A1 publication Critical patent/PE20140977A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

REFERIDO A UNA PREPARACION SOLIDA QUE COMPRENDE: A) UN INGREDIENTE FARMACEUTICAMENTE ACTIVO DE FORMULA (I); DONDE X E Y SON IGUALES O DIFERENTES Y CADA UNO ES UN ENLACE O UN ESPACIADOR QUE TIENE DE 1 A 20 ATOMOS EN LA CADENA PRINCIPAL, R1 ES UN GRUPO HIDROCARBONADO, R2, R3, Y R4 SON IGUALES O DIFERENTES Y CADA UNO ES UN ATOMO DE H, UN GRUPO HIDROCARBONADO, UN GRUPO TIENILO, ENTRE OTROS, R5 ES H O UN GRUPO HIDROCARBONADO OPCIONALMENTE SUSTITUIDO; B) OXIDO DE TITANIO; C) UN PLASTIFICANTE REPRESENTADO POR LA FORMULA: HOCH2(CH2OCH2)nCH2OH, DONDE n ES UN NUMERO ENTERO DE 2 - 870; Y D) UN ACIDO ORGANICO EN CADENA TAL COMO ACIDO OLEICO, ACIDO ADIPICO, ACIDO SUCCNICO, ACIDO SORBICO, ACIDO FUMARICO, ENTRE OTROS, QUE TIENE UN pH DE 6,0 O MENOS CUANDO SE DISUELVE O DISPERSA EN AGUA Y EL CONTENIDO PORCENTUAL DE DICHO ACIDO ES 0,01-50% EN PESO
PE2014000508A 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no peptidico PE20140977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28

Publications (1)

Publication Number Publication Date
PE20140977A1 true PE20140977A1 (es) 2014-08-20

Family

ID=41327301

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2011000089A PE20110591A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no peptidico
PE2014000933A PE20141585A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no petidico
PE2014000508A PE20140977A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no peptidico

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2011000089A PE20110591A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no peptidico
PE2014000933A PE20141585A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no petidico

Country Status (29)

Country Link
US (2) US9186411B2 (es)
EP (2) EP2564833B1 (es)
JP (2) JP5295356B2 (es)
KR (1) KR20110042334A (es)
CN (3) CN102164581A (es)
AR (1) AR072842A1 (es)
AU (1) AU2009277443A1 (es)
BR (1) BRPI0916689A2 (es)
CA (2) CA2936400C (es)
CL (1) CL2011000170A1 (es)
CO (1) CO6290638A2 (es)
CR (1) CR20110110A (es)
DO (2) DOP2011000033A (es)
EA (2) EA201170272A1 (es)
EC (1) ECSP11010855A (es)
ES (2) ES2660962T3 (es)
GE (2) GEP20146122B (es)
IL (2) IL210735A0 (es)
MA (1) MA32556B1 (es)
MX (1) MX2011000757A (es)
MY (2) MY169461A (es)
NZ (2) NZ602592A (es)
PE (3) PE20110591A1 (es)
SG (1) SG186685A1 (es)
TW (2) TW201010992A (es)
UA (1) UA103332C2 (es)
UY (1) UY32008A (es)
WO (1) WO2010013823A2 (es)
ZA (1) ZA201101198B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
CN110917130A (zh) * 2012-06-27 2020-03-27 武田药品工业株式会社 用盐稳定的胺和有机酸的液体制剂
AU2013319118B2 (en) 2012-09-19 2016-03-03 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration with improved elution and/or absorbency
WO2014160278A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Polymer system for securing implants in syringe needles
CN105330647A (zh) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
PH12018500236B1 (en) 2015-07-30 2023-12-06 Takeda Pharmaceuticals Co Tablet
CN105106203B (zh) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 富马酸沃诺拉赞的药物组合物及其制备方法
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN106860852A (zh) * 2017-02-17 2017-06-20 王清华 一种用于结合治疗胃病的粘液西药
BR112019022142A2 (pt) 2017-05-31 2020-05-12 Boehringer Ingelheim International Gmbh Composição farmacêutica e forma de dosagem farmacêutica compreendendo (e)-4-(2-(aminometil)-3-fluoroalilóxi)-n-terc-butilbenzamida, processo para sua preparação, métodos para tratamento e seus usos
SG11202000136YA (en) 2017-07-10 2020-02-27 Takeda Pharmaceuticals Co Preparation comprising vonoprazan
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN109288722B (zh) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 一种变色修正肤色的粉底及其制备方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
KR20230005280A (ko) * 2020-04-24 2023-01-09 독토르. 팔크 파르마 게엠베하 셀리악병을 위한 피리디논 유도체의 전신 제제
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN114053239A (zh) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 一种富马酸伏诺拉生药物组合物及制备方法
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
AU2021351536A1 (en) * 2020-10-01 2023-05-04 Imago Biosciences, Inc. Pharmaceutical formulations for treating diseases mediated by kdm1a
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
CN115364065B (zh) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 富马酸伏诺拉生片
CN115944743B (zh) * 2023-01-18 2025-08-08 山东诚成医药科技有限公司 一种富马酸伏诺拉生组合物及其制备方法
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN119970680B (zh) * 2023-11-10 2025-10-03 中国人民解放军军事科学院军事医学研究院 一种秋水仙碱缓释微丸及其制备方法
CN117462507B (zh) * 2023-12-28 2024-03-15 山东齐都药业有限公司 富马酸伏诺拉生药物组合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (fr) 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
JP4730985B2 (ja) 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6924292B2 (en) 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
US20050004139A1 (en) * 2001-07-30 2005-01-06 Takeshi Inamori Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient
CN1571664A (zh) * 2001-10-17 2005-01-26 久光制药株式会社 经皮吸收型制剂
WO2003074076A2 (en) 2002-02-28 2003-09-12 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
NZ535663A (en) 2002-03-07 2006-06-30 Boehringer Ingelheim Pharma Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (de) * 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
EP1648416A4 (en) 2003-07-18 2012-03-28 Santarus Inc PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP2005263788A (ja) 2004-02-17 2005-09-29 Sankyo Co Ltd インドリン化合物を含有する安定化された医薬組成物
KR20120064735A (ko) 2004-04-01 2012-06-19 아지노모토 가부시키가이샤 나테글리니드 함유 제제
JP2006001912A (ja) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd タンパク質製剤の安定化方法
EP1803709B1 (en) * 2004-09-30 2013-01-02 Takeda Pharmaceutical Company Limited Proton pump inhibitors
CA2582300A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
WO2007023931A1 (ja) 2005-08-25 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. 血中アルコール濃度上昇抑制用組成物
ATE504567T1 (de) * 2005-08-30 2011-04-15 Takeda Pharmaceutical 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl-substitutierte 1-h-pyrrolderivate als säuresekretionshemmer
JPWO2007074910A1 (ja) 2005-12-28 2009-06-04 武田薬品工業株式会社 放出制御固形製剤
US20100062063A1 (en) * 2006-09-15 2010-03-11 Astellas Pharma Inc. Light-stable solid pharmaceutical composition of ramosetron
JP5074052B2 (ja) 2007-02-13 2012-11-14 有限会社愛和ライト 遊技機
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2009041705A2 (en) 2007-09-28 2009-04-02 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds as proton pump inhibitors
EP2196459B1 (en) 2007-09-28 2016-11-02 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compound
JPWO2009066746A1 (ja) 2007-11-22 2011-04-07 国立大学法人 東京大学 組織癒着防止材および関節拘縮防止材

Also Published As

Publication number Publication date
AU2009277443A1 (en) 2010-02-04
NZ602592A (en) 2014-01-31
ES2660962T3 (es) 2018-03-26
IL228817A0 (en) 2013-12-31
US20110124687A1 (en) 2011-05-26
WO2010013823A2 (en) 2010-02-04
KR20110042334A (ko) 2011-04-26
MX2011000757A (es) 2011-02-24
UA103332C2 (ru) 2013-10-10
AR072842A1 (es) 2010-09-22
UY32008A (es) 2010-02-26
ES2669592T3 (es) 2018-05-28
TW201010992A (en) 2010-03-16
PE20110591A1 (es) 2011-09-15
TW201431552A (zh) 2014-08-16
EP2564833B1 (en) 2017-12-20
ZA201101198B (en) 2012-05-30
JP5295356B2 (ja) 2013-09-18
SG186685A1 (en) 2013-01-30
MA32556B1 (fr) 2011-08-01
DOP2011000033A (es) 2011-04-15
CN102743330B (zh) 2016-03-23
MY156305A (en) 2016-01-29
IL210735A0 (en) 2011-03-31
GEP20146166B (en) 2014-09-25
EP2309985A2 (en) 2011-04-20
CA2732243C (en) 2016-11-29
CA2732243A1 (en) 2010-02-04
US20130261156A1 (en) 2013-10-03
CR20110110A (es) 2011-04-28
JP2011529445A (ja) 2011-12-08
PE20141585A1 (es) 2014-11-13
EA201170272A1 (ru) 2011-10-31
CL2011000170A1 (es) 2011-06-10
BRPI0916689A2 (pt) 2015-11-17
CN102743330A (zh) 2012-10-24
NZ591344A (en) 2013-03-28
MY169461A (en) 2019-04-11
WO2010013823A3 (en) 2010-04-15
JP5593363B2 (ja) 2014-09-24
DOP2013000172A (es) 2013-11-15
US9186411B2 (en) 2015-11-17
CN104784180A (zh) 2015-07-22
EP2564833A1 (en) 2013-03-06
GEP20146122B (en) 2014-07-25
CA2936400A1 (en) 2010-02-04
CO6290638A2 (es) 2011-06-20
JP2013047239A (ja) 2013-03-07
ECSP11010855A (es) 2011-03-31
EA201201451A1 (ru) 2013-07-30
EP2309985B1 (en) 2018-03-14
CN102164581A (zh) 2011-08-24
CA2936400C (en) 2018-03-27

Similar Documents

Publication Publication Date Title
PE20140977A1 (es) Composicion farmaceutica estabilizada a base de un compuesto no peptidico
MY152535A (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
PE20051094A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico y procesos para su preparacion
PE20141552A1 (es) Composiciones farmaceuticas
PE20081882A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
AR075139A1 (es) Compuestos biciclicos para la reduccion de la produccion de beta-amiloide
CO5690607A2 (es) Compuestos de piridina como inhibidores de dipeptidil peptidasa iv
ECSP10010060A (es) Derivados de pirazol sustituídos
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
EA201170772A1 (ru) Органические соединения
ECSP099638A (es) Nuevo compuesto de adenina
CO6612278A2 (es) Composición acuosa antitranspirante/desodorante
CO6180507A2 (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
EA201270216A1 (ru) Фармацевтический состав
AR070117A1 (es) Compuesto de piridilamidina o su sal, y composicion fungicida agricola u horticola que lo contiene como ingrediente activo
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
CO6341610A2 (es) Compuesto heterociclilo aromatico que contiene nitrogeno.
ES2545810T3 (es) Proceso para estabilizar el contenido bacteriano de preparaciones mineral acuosas que comprendan carbonato cálcico natural molido y/o carbonato cálcico precipitado y/o dolomita y/o carbonato cálcico reaccionado en superficie
PE20081700A1 (es) Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
PE20091079A1 (es) Compuestos heterociclicos como moduladores npy y2
MX2009008028A (es) Agentes antiparasitarios.
PE20130179A1 (es) Nuevos derivados terciarios de 8-hidroxiquinolina-7-carboxamida
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics

Legal Events

Date Code Title Description
FA Abandonment or withdrawal